Alterations in Mucosal Immunity Identified in the Colon of Patients With Irritable Bowel Syndrome

Aerssens, Jeroen; Camilleri, Michael; Talloen, Willem; Thielemans, Leen; Göhlmann, Hinrich W. H.; Wyngaert, Ilse Van den; Thielemans, Theo; Hoogt, Ronald de; Andrews, Christopher N.; Bharucha, Adil E.; Carlson, Paula; Busciglio, Irene; Burton, Duane D.; Smyrk, Thomas C.; Urrutia, Raúl; Coulie, Bernard

doi:10.1016/j.cgh.2007.11.012

Cited by 112 publications

(86 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, Chang et al (14) have demonstrated a reduced expression of proinflammatory cytokines in the sigmoid colon of patients with IBS. There are also studies reporting colonic mucosal gene expression indicating compromised mucosal immunity in IBS and the downregulation of genes related to T cells and macrophages (15,16). Taken together, our data indicate the possibility of mucosal immune dysregulation rather than immunoactivation.…”

Section: Ibs Vs Control Groupsupporting

confidence: 53%

Does the number of mucosal immune cells differ in irritable bowel syndrome and its subtypes?

İliaz

Akyüz

Yeğen

et al. 2018

Turk J Gastroenterol

View full text Add to dashboard Cite

show abstract

Section: Ibs Vs Control Groupsupporting

confidence: 53%

Does the number of mucosal immune cells differ in irritable bowel syndrome and its subtypes?

İliaz

Akyüz

Yeğen

et al. 2018

Turk J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…The most important aberrations include visceral hypersensitivity, abnormal gut motility and autonomous nervous system dysfunction, the interactions of which are suggested to make the bowel function susceptible to a number of exogenous and endogenous factors, such as the GI microbiota, diet and psychosocial factors (recently reviewed by Karantanos et al, 2010). In addition, the presence of low-level inflammation in the GI mucosa of IBS patients has also been observed in several studies, including those reported by Aerssens et al (2008), Chadwick et al (2002) and Macsharry et al (2008).…”

Section: Introductionmentioning

confidence: 84%

Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives

2010

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder that has been associated with aberrant microbiota. This review focuses on the recent molecular insights generated by analysing the intestinal microbiota in subjects suffering from IBS. Special emphasis is given to studies that compare and contrast the microbiota of healthy subjects with that of IBS patients classified into different subgroups based on their predominant bowel pattern as defined by the Rome criteria. The current data available from a limited number of patients do not reveal pronounced and reproducible IBS-related deviations of entire phylogenetic or functional microbial groups, but rather support the concept that IBS patients have alterations in the proportions of commensals with interrelated changes in the metabolic output and overall microbial ecology. The lack of apparent similarities in the taxonomy of microbiota in IBS patients may partially arise from the fact that the applied molecular methods, the nature and location of IBS subjects, and the statistical power of the studies have varied considerably. Most recent advances, especially the finding that several uncharacterized phylotypes show non-random segregation between healthy and IBS subjects, indicate the possibility of discovering bacteria specific for IBS. Moreover, tools are being developed for the functional analysis of the relationship between the intestinal microbiota and IBS. These approaches may be instrumental in the evaluation of the ecological dysbiosis hypothesis in the gut ecosystem. Finally, we discuss the future outlook for research avenues and candidate microbial biomarkers that may eventually be used in IBS diagnosis. IntroductionWe are colonized from birth by a complex microbiota that affects health and disease. By far the greater part of this microbiota resides in the gastrointestinal (GI) tract, and can be considered as an organ within an organ (Bocci, 1992). As many of the GI tract microbes have not yet been cultured and are only recognized based on their 16S rDNA sequences, molecular high-throughput approaches have been developed to study the diversity and functionality of the thousands of phylotypes that have been predicted to be present in the GI tract (for a full review, see Zoetendal et al., 2008). These studies have revealed that the composition of the microbiota in healthy adults is highly subject-specific and stable, indicating an individual core. Comparative microbiota analyses between multiple healthy subjects indicate that a limited proportion of phylotypes are shared between individuals, forming a common core microbiota that is assumed to be functionally redundant (Qin et al., 2010;Tap et al., 2009;Turnbaugh et al., 2009). Recent metagenomic sequence analysis of the GI tract microbiota has confirmed this and defined a reference set of over three million unique genes that vastly exceeds the coding capacity of the human genome (Qin et al., 2010). Insight into the microbiota of healthy subjects allows comparisons with that of compromised...

show abstract

“…[18][19][20][21][22] Gene expression profiling in tissue samples taken from patients with IBS has been reported using sigmoid colonic mucosal tissue. 23 Although certain gene expression biomarkers have been recently reported in the literature, these markers were derived from data mining of a published inflammatory bowel disease study. 24 However, it is unknown whether there exist 'surrogate' transcriptional biomarkers in peripheral blood cells of patients with IBS.…”

Section: Introductionmentioning

confidence: 99%

A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads

Jones

Chey

Singh

et al. 2014

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Alterations in Mucosal Immunity Identified in the Colon of Patients With Irritable Bowel Syndrome

Cited by 112 publications

References 43 publications

Does the number of mucosal immune cells differ in irritable bowel syndrome and its subtypes?

Does the number of mucosal immune cells differ in irritable bowel syndrome and its subtypes?

Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives

A biomarker panel and psychological morbidity differentiates the irritable bowel syndrome from health and provides novel pathophysiological leads

Contact Info

Product

Resources

About